Generic Competition for Drugs Treating Rare Diseases

Abstract

Get full access to this article

View all access options for this article.

References

Luo ,

Sarpatwari , and

A.S.

Kesselheim , “Regulatory Solutions to the Problem of High Generic Drug Costs,” Open Forum Infectious. Diseases 2, no. 4 (2015): ofv179.

M.A.

Carrier ,

Levidow , and

A.S.

Kesselheim , “Using Antitrust Law to Challenge Turing’s Daraprim Price Increase,” Berkeley Technology Law Journal 31 (2016): 1379-1408.

Thomas

, “Patients Eagerly Awaited a Generic Drug. Then They Saw theP-price,” New York Times, February 23, 2018, available at <https://www.nytimes.com/2018/02/23/health/valeant-drug-price-syprine.html> (last visited October 24, 2020).

Maynard and

Furia-Helms , “FDA is Working to Bridge Gaps and Meet Needs for Rare Disease Product Development,” U.S. Food and Drug Administration, available at <https://www.fda.gov/news-events/fda-voices-perspectives-fda-leadership-and-experts/fda-working-bridge-gaps-and-meet-needs-rare-disease-product-development> (last visited October 24, 2020).

Sarpatwari ,

R.F.

Beall ,

Abdurrob ,

He , and

A.S.

Kesselheim , “Evaluating the Impact of the Orphan Drug Act’s Seven-Year Market Exclusivity Period,” Health Affairs 37 no. 5 (2018): 732-737.

Sarpatwari and

A.S.

Kesselheim , “Reforming the Orphan Drug Act for the 21st Century,” New England Journal of Medicine 381, no. 2 (2019): 106-109.

A.J.

Karter

et al., “Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE),” Health Services Research 53, no. 2 (2018): 1227-1247.

C.V.

Dave ,

Hartzema , and

A.S.

Kesselheim , “Prices of Generic Drugs Associated with Numbers of Manufacturers,” New England Journal of Medcine 377, no. 26 (2017): 2597-2598.

Gupta ,

A.S.

Kesselheim ,

Downing ,

Greene , and

J.S.

Ross , “Generic Drug Approvals Since the 1984 Hatch-Waxman Act,” JAMA Internal Medicine 176, no. 9 (2016): 1391-1393.

10.

C.S.

Hemphill and

B.N.

Sampat , “Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals,” Journal of Health Economics 31, no. 2 (2012): 327-339.

11.

“Ultra Orphan Drugs,”

The National Institute for Health and Care Excellence, 2004, available at <https://pubmed.ncbi.nlm.nih.gov/28230958/> (last visited October 22, 2020).

12.

See Gupta et al, supra note 9.

13.

R.F.

Beall ,

J.J.

Darrow , and

A.S.

Kesselheim , “A Method for Approximating Future Entry of Generic Drugs,” Value in Health 21, no. 12 (2018): 1382-1389.

14.

“FDA approves more generic drugs, but competition still lags: FY 2012-17 program achieves mixed results,”

The PEW Charitable Trusts, February 25, 2019, available at <https://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2019/02/fda-approves-more-generic-drugs-but-competition-still-lags> (last visited October 22, 2020).

15.

C.P.

Wiske ,

O.A.

Ogbechie , and

K.A.

Schulman , “Options to Promote Competitive Generics Markets in the United States,” JAMA 314, no. 20 (2015): 2129-2130.

16.

Liljenquist ,

Bai , and

G.F.

Anderson , “Addressing Generic-Drug Market Failures — The Case for Establishing a Nonprofit Manufacturer,” New England Journal of Medicine 378, no. 20 (2018): 1857-1859.

17.

A.S.

Kesselheim ,

C.L.

Treasure , and

Joffe , “Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage,” PLOS Medicine 14, no. 1 (2017): e1002190.